Overview

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Status:
Active, not recruiting
Trial end date:
2022-07-17
Target enrollment:
Participant gender:
Summary
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for these patients. But the optimal treatment schedule is controversial. The previous protocols usually contained high dose methotrexate, but the application of them is limited for the toxicity.
Phase:
Phase 3
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
Asparaginase
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Etoposide phosphate
Methotrexate
Pegaspargase